Assurance de qualité pour le cancer rectal – phase 2 ...

More documents

Recommendations

Info

152 PROCARE – phase 2 KCE reports 81Code Description Value(s)SG_V128 Surgical exploration metastasis 1 = no, 2 = exploration limited because ofadherences, 3 = yesSG_V168 Surgical resection 0 = no/missing, 1 = yesSG_V207 Perforation rectum? 0 = no/missing, 1 = yesSG_V209 Distal level resection (at SSO) 1 = rectum, 2 = anorectal (on top of the anal canal),3 = anal (intra-anal)SG_V210 Resection technique 1 = PME, 2 = TME, 3 = conventionalSG_V216 Type resection 1 = R0, 2 = R1, 3 = R2, 4 = uncertainSG_V234 Type reconstruction 1 = endoscopic polypectomy, 2 = local excision (discexcision), 3 = TEMS, 4 = APR, 5 = Hartmann, 6 =high anterior resection + CRA, 7 = low anteriorresection + CRA, 8 = restorative rectum resection(TME) + straight CAA, 9 = restorative rectumresection (TME) + colon J pouch, 10 = restorativerectum resection (TME) + coloplasty, 11 =restorative rectum resection (TME) + other, 12 =otherSG_V245 Derivative stoma 0 = no/missing, 1 = yesSPO_V102 Date postoperative death DateSPO_V104 Discharge date DateSPO_V117 Leakage of anastomosis 1 = minor, 2 = majorRD_V101 Radiotherapy treatment 1 = preoperative, 2 = postoperativeRD_V104 Date first irradiation DateRD_V105 Date last irradiation DateRD_V106 Number of fractions NumericRD_V107 Radiation compliance:0 = no/missing, 1 = yestreatment interruption of morethan five working daysRD_V109 Total dose given at ICRU Numericreference pointRD_V124 Concomittant chemotherapy 0 = no/missing, 1 = yesPT_V105 Distance anal verge NumericPT_V106 cTNM stagingPT_V111 Surface TME 1 = smooth & regular, 2 = mildly irregular, 3 =severely irregularPT_V122 Distance distal (cm) NumericPT_V127 Tumour perforation NumericPT_V140 Longitudinal margin distal 1 = free, 2 = invadedPT_V141 Circumferential margin (mm) NumericPT_V143 Number of invaded lymph NumericnodesPT_V149 RCRG 1 = grade 1, 2 = grade 2, 3 = grade 3PT_V150 RCR (Dworak) 1 = grade 0, 2 = grade 1, 3 = grade 2, 4 = grade 3, 5= grade 4PT_V151 Conclusion (y)pTNM 1 = pTNM, 2 = ypTNMPT_V152 Conclusion T 1 = Tx, 2 = T0, 3 = Tis, 4 = T1, 5 = T2, 6 = T3, 7 =T4PT_V153 Conclusion N 1 = N0, 2 = N1, 3 = N2, 4 = NxPT_V154 Conclusion M 1 = Mx, 2 = M1CH_V101 Preoperative chemotherapy 0 = no/missing, 1 = yeswith radiotherapyCH_V103 Preoperative chemotherapywithout radiotherapy0 = no/missing, 1 = yesCH_V104 Postoperative chemotherapy 0 = no/missing, 1 = yesCH_V105 Postoperative chemotherapy –specification1 = with radiotherapy, 2 = with radiotherapy andcontinuation of chemotherapy after radiotherapy, 3= chemotherapy alone
KCE Reports 81 PROCARE – phase 2 153Code Description Value(s)CH_V106 Postoperative chemotherapy 1 = adjuvant, 2 = palliativealone – specificationCH_V107 Palliative chemotherapy 0 = no/missing, 1 = yesCH_V109 Medication period 1 = during preoperative RT, 2 = preoperativechemotherapy without RT, 3 = postoperativechemotherapy during RT, 4 = postoperative adjuvantchemotherapy without RT, 5 = palliativechemotherapyCH_V110 Specification of chemotherapy 1 = 5-FU, 2 = oral fluoropyrimidines, 3 = otherCH_V112 Chemotherapy schedule Free textCH_V115 Medication periodCH_V119 Medication periodCH_V120 Specification of chemotherapy 1 = 5-FU, 2 = oral fluoropyrimidines, 3 = oxalliplatin,4 = irinotecan, 5 = otherCH_V122 Chemotherapy schedule Free textCH_V136 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – diarrheaCH_V137 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – nauseaCH_V138 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – vomitingCH_V139 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – anorexiaCH_V140 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – neutropeniaCH_V141 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – neutropenic fever orinfectionCH_V142 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – stomatitisCH_V143 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – neurotoxicityCH_V144 Chemotherapy-related adverse 0 = no/missing, 1 = yesevents – otherCH_V146 Type of adverse events - grade 1 = grade 3, 2 = grade 4FU_V102 Date of follow-up consultation DateFU_V105 Late complications radio- 0 = no/missing, 1 = yesand/or chemotherapyFU_V106 Late complications – skin 0 = no/missing, 1 = yesFU_V107 Late complications –0 = no/missing, 1 = yesgastrointestinalFU_V108 Late complications – bladder 0 = no/missing, 1 = yesFU_V109 Late complications – ureter 0 = no/missing, 1 = yesFU_V110 Late complications – nerves 0 = no/missing, 1 = yesFU_V111 Late complications – other 0 = no/missing, 1 = yesFU_V113 Stoma 1 = not applicable (never had), 2 = present, 3 =closedFU_V114 Date of stoma closure DateFU_V139 Local recurrence 0 = no/missing, 1 = yes
Page 1 and 2:
Assurance de qualitépour le cancer
Page 3 and 4:
Assurance de qualité pour lecancer
Page 5 and 6:
KCE Reports 81B Cancer rectal - pha
Page 7:
KCE Reports 81B Cancer rectal - pha
Page 10 and 11:
vi Cancer rectal - phase 2 KCE Repo
Page 12 and 13:
2 PROCARE - phase 2 KCE reports 81A
Page 14 and 15:
4 PROCARE - phase 2 KCE reports 811
Page 16 and 17:
6 PROCARE - phase 2 KCE reports 81F
Page 19 and 20:
KCE Reports 81 PROCARE - phase 2 92
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
KCE Reports 81 PROCARE - Phase 2 77
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112: KCE Reports 81 PROCARE - phase 2 10
Page 161: KCE Reports 81 PROCARE - phase 2 15
Page 169: KCE Reports 81 PROCARE - phase 2 15
Page 172 and 173: Dépôt légal : D/2008/10.273/39
Page 174 and 175: 35. Etude relative aux coûts poten
show all

Assurance de qualité pour le cancer rectal – phase 2 ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?